use of azithromycin in the treatment of acute exacerbations of copd
Clicks: 181
ID: 198389
2008
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Star Article
30.0
/100
181 views
21 readers
AI Quality Assessment
Not analyzed
Readership in this journal
StarRanked #27 of 88 articles by views in tijdschrift voor geneeskunde
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Aaron P MilstoneDivision of Allergy, Pulmonary and Critical Care, Vanderbilt University Medical Center, Nashville, TN, USAAbstract: Chronic bronchitis is a relatively common entity among patients with underlying chronic obstructive lung disease. Typical treatment includes pulmonary hygiene, bronchodilators, and antimicrobial therapy. In recent years, the duration of antimicrobial therapy in acute exacerbations of COPD has become shorter and shorter. This review summarizes the data on the use of the drug azithromycin for this particular patient population with a focus on 3-day and single-day therapy.Keywords: COPD acute exacerbation, macrolide, azithromycin
Abstract Quality Issue:
This abstract appears to be incomplete or contains metadata (89 words).
Try re-searching for a better abstract.
| Reference Key |
milstone2008internationaluse
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Aaron P Milstone |
| Journal | tijdschrift voor geneeskunde |
| Year | 2008 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.